Company intelligence / Profile preview

Fibrosoft

Sydney/Singapore/Brisbane, Singaporeconvention.bio.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Fibrosoft is developing a novel non-surgical injectable treatment for fibromatoses such as Dupuytren's contracture, Ledderhose disease, and Peyronie’s disease. Over 270 patients have been treated with a reported 30% improvement after the first injection and no serious adverse events observed to date. The company holds granted patents in Australia and the USA with European applications under accelerated prosecution. They are seeking licensees or VC funding to advance development.

Therapeutic areas: RheumatologyRare DiseasesMen's Health
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

fibrosoft

Pre-clinical

Indications: Dupuytren's contracture, Ledderhose's disease, Peyronie's disease

Partnerships

None disclosed; actively seeking licensee/VC partnerships

Beyond the preview

Go deeper on Fibrosoft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibrosoft.

Explore the full profile